Blog
RSS FeedPosted by Michael Wonder on 24 Aug 2023
PHARMAC seeking bids from suppliers for multiple myeloma treatments
24 August 2023 - PHARMAC is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the ...
Posted by Michael Wonder on 23 Aug 2023
PHARMAC confirms transition to a trastuzumab biosimilar and widens access to other types of cancer
23 August 2023 - PHARMAC is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin, as a result ...
Posted by Michael Wonder on 22 Aug 2023
Suggestions Nat's cancer drug funding promise has put PHARMAC in a difficult position
22 August 2023 - It's being suggested National's cancer drug funding promise has put PHARMAC in a difficult position. ...
Posted by Michael Wonder on 21 Aug 2023
National to roll back free prescription fees to pay for 13 cancer treatments
21 August 2023 - The National Party wants to bring back the $5 prescription fee for those who can afford ...
Posted by Michael Wonder on 16 Aug 2023
PHARMAC publishes agenda for this week's PTAC meeting
16 August 2023 - Another underwhelming agenda that was only published after agitation on social media. ...
Posted by Michael Wonder on 15 Aug 2023
PHARMAC indicates interest to fund more oestradiol treatments to relieve supply issue
15 August 2023 - PHARMAC is planning to issue a competitive process for supply of oestradiol transdermal products in New Zealand. ...
Posted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 10 Aug 2023
PHARMAC’s Rare Disorders Advisory Committee makes new recommendations for funding
10 August 2023 - PHARMAC has published the record of the March Rare Disorders Advisory Committee meeting, sharing details on ...
Posted by Michael Wonder on 01 Aug 2023
PHARMAC considers access criteria for COVID-19 anti-viral treatments
1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include ...
Posted by Michael Wonder on 31 Jul 2023
New Zealand Pharmaceutical Schedule - 1 August 2023
1 August 2023 - The August 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Jul 2023
Molnupiravir will remain available for people who need it
27 July 2023 - PHARMAC has confirmed today that molnupiravir will remain available as a treatment to protect against infection ...
Posted by Michael Wonder on 01 Jul 2023
New Zealand Pharmaceutical Schedule - 1 July 2023
1 July 2023 - The July 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jun 2023
PHARMAC considers widening access to treatments for multiple sclerosis and haemophilia A
22 June 2023 - PHARMAC has started a consultation today for widening access for two treatments; ocrelizumab (Ocrevus) as the first ...
Posted by Michael Wonder on 09 Jun 2023
PHARMAC breast cancer cost saving proposal welcome but ignores patients facing “dead-end”
8 June 2023 - Breast Cancer Foundation NZ is urging PHARMAC to widen access to an already funded treatment for ...
Posted by Michael Wonder on 08 Jun 2023
Proposal to widen access to intravenous trastuzumab and change the funded brand
8 June 2023 - The proposal would also give more New Zealanders funded access to intravenous trastuzumab. ...